Masafumi Nakamura1, Hiroshi Nakashima2, Toshiya Abe2, Takaaki Ensako2, Koji Yoshida3, Keisuke Hino3. 1. Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan mnakamura@med.kawasaki-m.ac.jp. 2. Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan. 3. Department of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki, Japan.
Abstract
AIM: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. PATIENTS AND METHODS: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using χ(2) for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. RESULTS: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). CONCLUSION: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections. Copyright
AIM: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. PATIENTS AND METHODS: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using χ(2) for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. RESULTS: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). CONCLUSION: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections. Copyright
Authors: Richard S Hoehn; Koffi Wima; Audrey E Ertel; Alexandra Meier; Syed A Ahmad; Shimul A Shah; Daniel E Abbott Journal: J Gastrointest Surg Date: 2015-08-21 Impact factor: 3.452
Authors: Se-Il Go; Young Saing Kim; In Gyu Hwang; Eun Young Kim; Sung Yong Oh; Jun Ho Ji; Haa-Na Song; Se Hoon Park; Joon Oh Park; Jung Hun Kang Journal: Cancer Res Treat Date: 2016-02-12 Impact factor: 4.679
Authors: Liu Wensheng; Zhang Bo; Hu Qiangsheng; Xu Wenyan; Ji Shunrong; Xu Jin; Ni Quanxing; Yu Xianjun; Xu Xiaowu Journal: Cancer Cell Int Date: 2019-09-09 Impact factor: 5.722
Authors: Muhammet Ozer; Suleyman Y Goksu; Nina N Sanford; Matthew Porembka; Hajra Khurshid; Chul Ahn; Mary Claire Maxwell; Muhammad Shaalan Beg; Syed M Kazmi Journal: JAMA Netw Open Date: 2022-02-01